LB1908

About Legend Biotech

Legend Biotech's mission is to discover, develop, and commercialize transformative cell therapies for patients with life-threatening diseases, primarily in oncology. Its core achievement is the successful global launch of CARVYKTI® (cilta-cel), a best-in-class CAR-T therapy for multiple myeloma, which has propelled the company to commercial leadership and validated its technology platform. The company's strategy centers on deepening its commercial footprint, advancing a broad pipeline of next-generation cell therapies, and expanding its manufacturing capabilities, all underpinned by a strategic global collaboration with Janssen (Johnson & Johnson).

Therapeutic Areas